Abstract: Calcium-containing compounds have been at least partly film-coated and/or granulated with a water-soluble substance and a water-soluble polymeric substance and use of such coated compounds in pharmaceutical compositions. The at least partly film-coated and/or granulated calcium-containing compounds have proved suitable for the preparation of tablets having a very high load of elemental calcium and a conveniently small size. A drug load of about 96% or more is obtained in tablets of the invention that have sufficient mechanical and organoleptic properties.

Abstract: The present disclosure relates generally to the field of mucositis. More particularly, methods and compositions for treating, ameliorating and/or preventing mucositis are provided by administering a clay to the subject in need.

Abstract: Disclosed are dental compositions and methods. In accordance with one embodiment, a dental composition includes calcium, fluorine, which is generally present in the form of fluoride, and phosphate or another stabilizing anion. The composition is stable as against precipitation of calcium fluoride during transport and storage, but is unstable against the precipitation of calcium fluoride in the oral cavity of a human. In many embodiments, the amount of fluoride may be less than the amount of fluoride used in a comparable composition intended for a similar purpose. A dental method comprises applying the composition to the oral cavity of a patient, whereupon calcium fluoride precipitates from the composition.

Abstract: Disclosed are systems, methods, compositions and kits for mineralizing tissue, particularly dental tissue. The methods, compositions and kits may be used to strengthen and prevent weakening of the tissue. For example, the methods, compositions and kits may be used for treating and filling cavities in teeth caused by tooth decay.

Abstract: Compositions are provided for preferential distribution of active agents to injury sites. Such compositions may comprise a ligand with hydrophilic properties and one or more active agents, such as compounds comprising hydrophilic metal ions. Because the delivery ligand and the active agent are specifically selected so the interactions between them are mainly of an ionic nature so that binding of the active agent to the delivery ligand and release of the active agent into the target site are not dependent on enzymatic activity. Methods of using such compositions are also disclosed.

Abstract: Biguanide-preserved precipitated calcium carbonate oral care compositions and methods of manufacture thereof are disclosed.

Abstract: The present invention provides compositions comprising sugar, cysteine, and/or sugar-cysteine products, methods of preparing the same, and/or using the same.

Abstract: Methods of treating hemorrhage are provided, comprising diagnosing one or more hemorrhaging or potentially hemorrhaging vessels in a patient and administering to the patient a therapeutically effective amount of a composition comprising a vessel closing compound at a concentration between about 0.1% and about 45%. The vessel closing compound may comprise a polymer with hydrophilic properties, such as polyethylene glycol (PEG). The composition may also comprise one or more active agent such as a blood flow modifier with a potential to form ionic bonds with the vessel closing agent.

Abstract: Dialysis fluid compositions including 0.5 to 3 mM citrate, 1 to 5 mM total calcium, and 0 to 1.5 mM total magnesium. These dialysis fluid compositions include 0.10 to 0.2 mM more total calcium per 1 mM citrate within the dialysis fluid as compared to the calcium concentration ordinarily prescribed for a non-citrate containing dialysis fluid.

Abstract: The therapeutic device is an acupuncture device which is usable for treating chronic, but non-contagious diseases. The device is in the form of a solid chip or tablet having a unique composition, which can be placed on the body of a patient's acupuncture meridian points for the treatment. The treatment with this device is safe, more effective, non-invasive and easy to use over other alternative treatments because it does not involve the use of needles, medication, electricity and radiation.

Abstract: A bioscaffolding can be formed within a post-myocardial infarct region sufficient to cause attenuation of a rate of myocardial infarct expansion. A bioscaffolding may further be formed in the post-myocardial infarct region to cause an increase in posterior left ventricular wall thickness. The gel or bioscaffolding can be formed from a mixture of gel components of different gelation systems. For example, a bioscaffolding can be formed by mixing at least two different components of at least two different two-component gelation systems to form a first mixture and by mixing at least two different components (other than the components that make up the first mixture) of the at least two different two-component gelation systems to form a second mixture.

Abstract: A nutritional supplement composition for treating nutritional deficiencies caused by a medical condition in subjects is disclosed. The present application further discloses a method of using a nutritional supplements composition for treating a subject with complications resulting from sickle cell anemia. The method comprises administering to a subject an effective amount of the nutritional supplement.

Abstract: Compositions and methods for relieving symptoms of rheumatoid arthritis (RA) and related illnesses are disclosed. It appears that the primary cause of RA is a sensitivity or hypersensitivity to potassium and/or vitamin C, or too much potassium and/or vitamin C in the diet. The effects of potassium and vitamin C on the body must be modified to relieve the symptoms of RA and related illnesses. It appears that magnesium does not cause the inflammation, but appears that it exacerbates the problem. It appears that calcium and vitamin D intake, possibly in combination with the reduced or no intake of potassium and/or vitamin C, may also help to relieve the symptoms of RA and related illnesses.

Abstract: The invention provides methods and kits for treatment of pain or inflammation. In one embodiment, the kit comprises a biomembrane sealing agent, such as PEG, and a bioactive agent, such as a magnesium compound. The biomembrane sealing agent and/or the bioactive agent an intravenous administration, an intramuscular administration, an intrathecal administration, a subcutaneous administration, an epidural administration, a parenteral administration, an intra-articular administration, a direct application onto or adjacent to a site of the pathological condition, and any combinations thereof. Alternatively, the biomembrane sealing agent and/or the bioactive agent may be delivered from a pump or an implant.

Abstract: The present invention is directed to a wound composition comprising an effective amount of phenyloin and an effective amount of vitamin C. The present invention is further directed to a method of treating a wound in a patient comprising administering an effective amount of phenyloin and an effective amount of vitamin C to the wound.

Abstract: A composition to be administered to a mammal for treating hearing loss is disclosed herein. The composition consists essentially of a biologically effective amount of vitamin A, vitamin C, vitamin E, and a vasodilator comprising magnesium. The composition optionally includes a withanolide and/or resveratrol. The vitamin A, vitamin C, vitamin E, and the vasodilator comprising magnesium provides an additive effect that is equal to or greater than a sum of the effects of the individual components.

Abstract: A method is provided for promoting blood clotting. The area which is bleeding is contacted with an aluminophosphate molecular sieve. The molecular sieve preferably contains a substance which assists the clotting of blood. This substance is preferably Ca2+ ions, which are readily introduced into aluminophosphate molecular sieves. Preferred aluminophosphate molecular sieves include AlPO4-5 and VPI-5.

Abstract: There is disclosed a formulation of a transdermal skin treatment effective in inhibition of itch sensation. In an embodiment, the formulation includes a solvent mixture of alcohols, glycols and water combined to provide a solubility parameter between 20 Pa0.5 and 40 Pa0.5, the solvent mixture having an average normal boiling temperature of at least 100° C., the solvent mixture having at least 0.04 mols/liter of multivalent cations, the solvent mixture containing at least one local anesthetic, and the solvent mixture having pH exceeding 8.0, with a thixotropic flow characteristic accomplished by an organic gellant. Other embodiments are also disclosed.

Abstract: The present disclosure provides biomaterials and methods for preventing and minimizing progression of cartilage and/or connective tissue damage. Also provided herein are biomaterials and methods for alleviating and/or reducing the risk for developing arthritis (e.g., osteoarthritis) associated with joint injury and/or joint surgery.

Abstract: An absorbable encapsulated calcium in hypromellose capsule, characterized in that the encapsulated calcium comprises calcium amino acid chelate extracted from soya bean, aspartate, calcium amino acid chelate which is obtained from chelation of aspartate with calcium hydroxide, collagen, lecithin, soya bean extract, lactose, calcium carbonate, in the ratio of 4:8:8:10:8:12:10:40 being capsulated into hypromellose capsule capable of being absorbed in vivo at the small intestine beyond the stomach, which maximize human absorption of calcium.

Abstract: Disclosed are high loading, controlled-release dosage forms for oral administration of magnesium salts. For example, an oral dosage form can comprise from about 80% to about 95% magnesium lactate and one or more components. As another example, an oral dosage form can comprise at least about 50% magnesium salt and exhibit a controlled release dissolution profile. Also disclosed are methods for making controlled release dosage forms for oral administration of a therapeutically effective amount of magnesium salt to a mammal. Also disclosed are methods for treating a disorder characterized by magnesium deficiency and methods for preventing or alleviating low magnesium levels.

Abstract: A synergistic composition, or the use of that composition in the manufacture of a medicament, or a method of treatment including the use of that composition, for the treatment of hair loss and baldness, for combined, sequential or simultaneous administration, in any form, via any biological route. In its optimal embodiment the composition consists, in the form of a lotion: 1600-2400 IU/mL Vitamin A Palmitate, 0.64%-0.96% Thiamine Hydrochloride, 0.64%-0.96% Pyridoxine Hydrochloride, 4.8%-7.2% Niacinamide, 2.85%-5.2% D-Panthenol, 1.6%-2.4% L-Arginine, 3.6%-4.4% Methyl Sulphonyl Methane (MSM), 0.08%-0.12% Ginger Oil, 0.08%-0.12% Cinnamon Oil, 0.0996%-0.1494% Oleoresin Capsicum, 1.3%-1.95% Magnesium, 2.4%-3.6% Zinc, 0.192%-0.288% Manganese, 2.6%-3.9% Urea, 2.4%-3.6% Sodium Glycerophosphate, 4.8%-7.2% L-Lysine HCl, plus Preservatives, Co-solvent (Propylene Glycol), Fragrances, Anti-Oxidant, Cooling agent (Menthol), Emulsifier, and Vehicle (Purified water).

Abstract: The present invention provides a solution for peritoneal dialysis, consisting of at least two single solutions which are combined after a heat sterilization and are administered to a patient, the first single solution containing an osmotic and the second single solution containing a buffer, and one of these single solutions or another single solution containing electrolyte salts. Glucose-like degradation and hydrolysis is avoided during sterilization and storage, while maintenance of a neutral mixture pH is achieved by the osmotic comprising a glucose polymer and/or glucose polymer derivative, and the pH of the first single solution being between 3.5 and 5.0. The present invention further discloses a twin-chambered pouch consisting of a plastic pouch with at least one first chamber and a second chamber, the first single solution being included in the first chamber and the second single solution being included in the second chamber.

Abstract: The present invention provides a stabilized pesticidal composition comprising at least one granular substrate material containing at least one metal chelate of 2-(2?-nitro-4?-methylsulphonylbenzoyl)-1,3-cyclohexanedione, a method of producing a stabilized granular pesticidal composition which comprises incorporating a metal chelate of 2-(2?-nitro-4?-methylsulphonylbenzoyl)-1,3-cyclohexanedione in to or on to a granular substrate material; and a method of killing or controlling weeds or unwanted vegetation (without damaging beneficial plants and or seeds) which comprises applying a herbicidally effective amount of the stabilized granular pesticide composition of the invention to the foliage, tissue or locus of the weeds or unwanted vegetation.

Abstract: A wipe that includes a bacteriostatic agent that contains cations having an affinity for the negatively charged cell walls of bacteria is provided. The affinity of the bacteriostatic agent for the bacteria allows the wipe to capture bacteria, thereby removing them from a surface and also inhibiting their spread to other surfaces that may contact the wipe. Of particular advantage, the bacteriostatic agent may help protect against the spread or infection of pathogens without the use of chemicals, such as antiseptics or antibiotics. Still further, the wipe of the present invention also contains a solvatochromatic indicator that undergoes a color change in the presence of a broad spectrum of bacteria. Thus, when the wipe captures bacteria, the indicator undergoes a color change that signals to the user that the wipe is functioning properly. The lack of a color change may likewise provide the user with the assurance that the area is generally free of bacteria and clean.

Abstract: The present invention relates to a composition for the use in improving vascular health, including treating and preventing vascular diseases and diseases related thereto, using a botanical extract of oil palm vegetation liquor from the palm oil milling process.

Abstract: Various exemplary embodiments provide protocell nanostructures and methods for constructing and using the protocell nanostructures. In one embodiment, the protocell nanostructures can include a core-shell structure including a porous particle core surrounded by a shell of lipid bilayer(s). The protocell can be internalized in a bioactive cell. Various cargo components, for example, drugs, can be loaded in and released from the porous particle core of the protocell(s) and then delivered within the bioactive cell.

Abstract: Described herein are food formulations and methods, which promote sleep.

Abstract: The invention relates to an unexpected discovery that propylene glycol is highly effective at killing or inhibiting Propionibacterium acnes in a mammalian skin disorder, as well as to the use of propylene glycol and salicylic acid in a skin-disorder treatment. This invention also relates to compositions containing propylene glycol alone or in combination with salicylic acid for use in killing or inhibiting Propionibacterium acnes.

Abstract: Beta glucan and fulvic acid can be combined in a dietary supplement as a partial substitute or complete replacement for blue green algae and/or brown seaweed and its derivatives. Beta glucans are widely available as derivatives of Brewer's yeast and fulvic acid is widely available as well. These supplements are not subject to the vagaries of weather-influence growing seasons as is the case with blue green algae and brown seaweed. When combined, beta glucan and fulvic acid can provide a less costly dietary supplement than blue green algae and brown seaweed and its derivatives such as fucoidan.

Abstract: The invention relates to an aqueous liquid composition of calcium acetate, sweetener, and taste masking agent. Also provided is a method for binding phosphorus within the gastrointestinal tract of an individual by administering to the individual an aqueous solution of at least calcium acetate.

Abstract: Low foaming, highly acidic peroxycarboxylic acid sanitizing compositions are disclosed as having both improved antimicrobial efficacy in comparison to conventional peroxyoctanoic acid and peroxyacetic acid compositions for sanitizing applications. The compositions include a combination of a low-foaming surfactant and an aluminum sulfate (or other metal salt) defoaming agent that is compatible with the highly acidic peroxycarboxylic acid sanitizing compositions. In particular, the sanitizing peroxycarboxylic acid compositions are also low odor and low/no VOC dual functioning acid wash and sanitizing compositions.

Abstract: An oral dosage form for administration to an animal comprising a biologically utilizable form of calcium and an extended release system that maintains the calcium level in the animal's bloodstream at a substantially beneficial level for a defined period of time.

Abstract: The present invention utilizes a nano-coating of an oxide such as silica, a silicate or another effective oxide on a surface to accelerate blood clotting in mammalian animals. The hemostatic layer has a thickness that is effective for the hemostasis, yet can be made thin enough to result in a resorbable film which can either be applied to a biocompatible or resorbable device that can be used in surgical applications as well as in topical applications such as trauma.

Abstract: A Copper/Zinc superoxide dismutase (Cu/Zn SOD) composition comprising a therapeutically effective amount of ionic mineral(s) in a ligand complex and a pharmaceutically acceptable carrier for the neutralization of superoxide produced trauma and/or stress-related conditions including, but not limited to, conditions such as myotrophic lateral sclerosis (ALS). The composition may also include other supporting adjutants such as bioavailable magnesium, manganese, selenium and other minerals that can support the nervous system and other vitamins and glutathione and other nutrients. Botanical extracts, urea, other supplements helpful for protection and re-enforcement of the immune system are discussed.

Abstract: The present invention relates to a personal care composition that contains a rinse-off composition which deposits at least 0.5 ?g/cm2 of shiny particles on the skin. Preferably, the shiny particles are hydrophobically modified interference pigments. The inventors have found that hydrophobically modifying the particles significantly improves the deposition of the particles on skin from rinsable compositions.

Abstract: The present invention relates to methods of prognosing the survival of a diseased subject, particularly a subject with chronic kidney disease (CKD), as well as selecting an end-stage renal disease subject for a kidney transplant. The methods involve detecting an elevated amount of macrophage inhibitory cytokine-1 (MIC-1) in a test body sample from the diseased subject. A method of preventing or reducing the risk of death in a CKD subject which involves removing or inactivating MIC-1 present in the blood, plasma or serum of the subject, is also disclosed.

Abstract: The present invention relates to liquid application for skin rejuvenation created from specific amino acids, lipids, nucleic acids and vitamins. This collection of molecules delivers precisely the factors necessary to a specific site requiring healing; a direct intervention system to most expeditiously remodel skin with building blocks. This delivery is a transdermal topical delivery and healing is via specific molecules that engender a false autocoid reaction rapidly followed by an incremental healing-anti-inflammatory response augmented by very specific GRAS ingredients in the invention and also recruited from the body to this needy site. Energy is brought to site by transdermally delivered protons and enhanced by the local vascular flow initiated by transdermal molecules. This delivery system bypasses digestion and dilution. Key is a lipophilic carrier with nuclear and mitochondrial ligands that rapidly penetrate and permeate all membranes and truncates the inflammatory site quickly manifesting curation.

Abstract: The present invention is in the fields of medicine, pharmaceuticals, neutraceuticals and rheumatology. The invention provides pharmaceutical compositions for the treatment and/or prevention of osteoarthritis in mammals, particularly humans, comprising sodium bicarbonate and calcium gluconate, and optionally comprising one or more additional components. The invention also provides methods of treating or preventing osteoarthritis by administering to a mammal, preferably via intraarticular injection, one or more compositions of the invention.

Abstract: The present invention generally relates to bioactive antibacterial materials and composites that enhance bone growth while preventing surgical site infection. The present invention also relates to bioactive antibacterial materials and composites that include a bimodal bioactive glass particle size distribution. The bioactive antibacterial composite finds utility in a variety of clinical applications including spine and orthopaedic procedures.

Abstract: Methods of using an ETB receptor agonist, such as IRL-1620, for the treatment of stroke or cerebrovascular accidents are disclosed. The ETB receptor agonist is used alone or in combination with a second agent useful in the treatment of stroke or other cerebrovascular accident.

Abstract: The present invention relates to the a method of inhibiting bone resorption in a mammal in need thereof with an oral pharmaceutical composition comprising a cathepsin K inhibitor, or a pharmaceutically acceptable salt thereof, or a mixture thereof, according to a continuous schedule having a dosage interval of once weekly, biweekly, twice monthly or once monthly.

Abstract: Disclosed are compositions of matter useful for the treatment of diabetes. In one embodiment a nutraceutical composition is administered to a patient in need, said composition comprising of one or more ingredients selected from a group consisting of: magnesium, chromium picolinate, alpha lipoic acid, Garcina indica, holy basil, Morodica charantica, cinnamon, Salacia reticulate, Salacia oblonga, Gymnema sylvestre, nopal cactus, fenu greek, vanadium, 1-carnitine, and vitamin D3.

Abstract: A cosmetic composition comprising at least one compound selected from bioactive/biocompatible microparticulates such as bioactive glass or bioactive ceramics, and an intradermal delivery vehicle selected from the group consisting of hyaluronans, hyaluronic acid and/or salts thereof and/or homologues, analogues, derivatives, complexes, esters, fragments and subunits of hyaluronic acid in an amount sufficient to facilitate deposition and penetration of said bioactive microparticulates through tissue at a site to be treated.

Abstract: The present invention relates to particulate UV protection agents which are obtainable by hydrothermal treatment of a particulate metal oxide and subsequent application of a manganese oxide coating, and to the preparation and use thereof. The present invention furthermore relates to novel compositions, in particular for topical application, which are intended, in particular, for light protection of the skin and/or hair against UV radiation and free-radical-induced stress, and to the use thereof in the above-mentioned cosmetic application.

Abstract: Demineralized bone matric (DBM) and native bone morphogenetic protein (nBMP) are complex mixtures of non-collagenous bone proteins. These mixtures contain many of the BMPs that are available as recombinant molecules. Information regarding the presence in these materials of molecules that may affect the availability and activity of the BMPs is very limited. A chemical extraction of DBM, such as using alkali-urea produces a water soluble extractate which inhibits the osteogenic activity of DBM. Noggin, an extracellular BMP ligand antagonist is found in the water soluble extractate from DBM. Differential chemical extraction is a useful means of removing non-osteogenic, or osteogenic inhibitory molecules from DBM and nBMP.

Abstract: Dental compositions are disclosed. A dental composition can include a reaction produce of a reaction mixture comprising a first mixture and a second mixture. The first mixture can include a ceramic based biomaterial, and the second mixture can include mineral trioxide aggregate and a phosphoric acid monomer.

Abstract: A drug delivery system for the controlled release of a pharmaceutically-active compound by oral route comprises an intercalate of a layered double hydroxide having, before intercalation, layers of metal hydroxides, and having intercalated therein a pharmaceutically-active compound having at least one anionic group. A preferred layered double hydroxide is one that has layers which comprise [LiAl2(OH)6]+. The drug delivery system has use in the delivery of drugs such as 4-biphenylacetic acid, Diclofenac, Gemfibrozil, Ibuprofen, Naproxen, 2-Propylpentanoic acid and Tolfenamic acid.

Abstract: Disclosed herein is a non-toxic, bioresorbable, magnesium based alloy for use in production of implants. Specifically exemplified herein are alloy embodiments useful for orthopedic implants. Also disclosed are alloy materials that incorporate magnesium, calcium and strontium.

Abstract: Antimicrobial agents and methods for the abatement of food borne pathogenic organisms—particularly, Escherichia coli—include the steps of providing a specifically formulated humic composition and, thereafter, applying the humic composition as an antimicrobial agent for the abatement of Escherichia coli. In at least some applications of the present invention, other substances are introduced in combination with the humic composition thereby synergistically providing in certain applications a greater effect than otherwise independently obtainable.